Chronic Lymphocytic Leukemia New Reference: Obinutuzumab, ibrutinib, and venetoclax for Untreated CLL Ulas D. Bayraktar, MD 2023-09-23
Diffuse Large B Cell Lymphoma New Protocol: Rituximab, Lenalidomide, and Ibrutinib in DLBCL Ulas D. Bayraktar, MD 2023-06-14
Mantle cell lymphoma New Protocol: Ibrutinib with Rituximab and Bendamustine for Mantle Cell Lymphoma Ulas D. Bayraktar, MD 2022-09-20
